A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

NCT05670925 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Camrelizumab plus Famitinib with/without nab-Palitaxel

Sponsor

Fudan University